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Abstract
Background: Cervical insufficiency is a risk factor for spontaneous midtrimester abortion or 
early preterm birth. Intra-amniotic infection has been reported in 8–52% of such patients, and 
intra-amniotic inflammation in 81%. Some professional organizations have recommended 
perioperative antibiotic treatment when emergency cervical cerclage is performed. The use of 
prophylactic antibiotics is predicated largely on the basis that they reduce the rate of complications 
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during the course of vaginal surgery. However, it is possible that antibiotic administration can also 
eradicate intra-amniotic infection/inflammation and improve pregnancy outcome.
Objective: To describe the outcome of antibiotic treatment of patients with cervical insufficiency 
with either intra-amniotic infection/inflammation.
Study design: The study population consisted of 22 women who met the following criteria: 1) 
singleton pregnancy; 2) painless cervical dilatation of >1cm between 16.0–27.9 weeks of 
gestation; 3) intact membranes and absence of uterine contractions; 4) transabdominal 
amniocentesis performed for the evaluation of the microbiologic and inflammatory status of the 
amniotic cavity; 5) presence of intra-amniotic infection/inflammation; and 6) antibiotic treatment 
(regimen consisted of ceftriaxone, clarithromycin, and metronidazole). Amniotic fluid was 
cultured for aerobic and anaerobic bacteria and genital mycoplasmas, and polymerase chain 
reaction (PCR) for Ureaplasma spp. was performed. Intra-amniotic infection was defined as a 
positive amniotic fluid culture for microorganisms or a positive PCR for Ureaplasma spp., and 
intra-amniotic inflammation was suspected when there was an elevated amniotic fluid white blood 
cell count (≥19 cells/mm3) or a positive rapid test for metalloproteinase-8 (MMP-8) (sensitivity 10 
ng/mL). For the purpose of this study, the “gold standard” for diagnosis of intra-amniotic 
inflammation was an elevated interleukin (IL)-6 concentration ≥2.6 ng/mL using ELISA. The 
results of amniotic fluid IL-6 were not available to managing clinicians. Follow-up amniocentesis 
was routinely offered to monitor the microbiologic and inflammatory status of amniotic cavity and 
fetal lung maturity. Treatment success was defined as resolution of intra-amniotic infection/
inflammation or delivery ≥34 weeks.
Results: 1) Of 22 patients with cervical insufficiency and intra-amniotic infection/inflammation, 
three (13.6%) had microorganisms in the amniotic fluid; 2) of the 22 patients, six (27%) delivered 
within one week of amniocentesis, and the remaining 16 (73%) delivered more than one week 
after the diagnostic procedure. Among these, twelve had a repeat amniocentesis to assess the 
microbial and inflammatory status of the amniotic cavity; 3) in 75% (9/12), there was objective 
evidence of resolution of intra-amniotic inflammation or infection demonstrated by analysis of 
amniotic fluid at the time of repeat amniocentesis; and 4) of the four patients who did not have a 
follow-up amniocentesis, all delivered ≥34 weeks, two of whom delivered at term; thus, treatment 
success occurred in 59% (13/22) of cases.
Conclusion: In patients with cervical insufficiency and intra-amniotic infection/inflammation, 
administration of antibiotics (ceftriaxone, clarithromycin, and metronidazole) was followed by 
resolution of the intra-amniotic inflammatory process or infection in 75% of patients, and was 
associated with treatment success in about 60% of cases.
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The term “cervical insufficiency” refers to a condition in which patients present with a 
dilated cervix in the midtrimester of pregnancy, protruding membranes in the absence of 
uterine contractions, or vaginal bleeding.1 The standard treatment is placement of an 
emergency cerclage.1–19 The best scientific evidence in support of this intervention derives 
from a randomized clinical trial that included patients with cervical insufficiency (i.e. 
membranes at or below a dilated external cervical os, before <27 weeks) treated with bedrest 
and antibiotics, and who were randomly assigned to emergency cerclage and indomethacin 
vs. bedrest only.2 Patients who received emergency cerclage, indomethacin, and antibiotics 
had a significantly lower rate of preterm delivery <34 weeks, than those allocated to bedrest 
and antibiotics (53.8% [7/13] vs. 100% [10/10], p=0.02).2
Intra-amniotic infection ascertained by amniocentesis has been reported in 8–52% of 
patients presenting with cervical insufficiency.20–27 The use of a cervical cerclage in such 
patients leads to uniformly poor results, since women develop clinical chorioamnionitis, 
rupture of the chorioamniotic membranes, or vaginal bleeding and require delivery.21 In 
contrast, patients with cervical insufficiency but without intra-amniotic infection who 
undergo cerclage placement have a better pregnancy outcome.21,22,25
Microorganisms and their products (i.e. endotoxin,28,29 peptidoglycans, or glucans30) can 
elicit an intra-amniotic inflammatory response,31–45 which is easily determined by 
measuring amniotic fluid pro-inflammatory cytokines [such as interleukin (IL)-6 or matrix 
metalloproteinase-8 (MMP-8)].46–93 Intra-amniotic inflammation can also be present in 
patients with cervical insufficiency23,94,95 and is associated with preterm delivery, as well as 
adverse pregnancy and neonatal outcomes.23,94 A subset of patients with intra-amniotic 
inflammation has no demonstrable microorganisms and, therefore, represents examples of 
sterile intra-amniotic inflammation, caused by danger signals or alarmins,96–102 which 
activate the inflammasome. Inflammasome activation can lead to preterm delivery.90,103–108
The traditional view has been that intra-amniotic infection in patients with cervical 
insufficiency cannot be successfully treated, and the same is the case for intra-amniotic 
inflammation. The objective of this report is to communicate a case series in which women 
with cervical insufficiency and intra-amniotic infection/inflammation were treated with 
antimicrobial agents, and this resulted in eradication of intra-amniotic infection/
inflammation in a subset of patients.
Materials and Methods
Study design
This was a retrospective case series study of patients admitted to Seoul National University 
Hospital between January 2004 and April 2014 who met the following criteria: 1) singleton 
gestation; 2) midtrimester painless cervical dilatation (>1cm) with visible membranes 
through the cervical os and intact membranes confirmed by sterile speculum examination; 3) 
gestational age between 16–27.9 weeks; 4) absence of uterine contractility according to the 
patient and uterine tocodynamometer; 5) transabdominal amniocentesis to evaluate the 
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microbiologic and inflammatory status of the amniotic cavity; 6) presence of intra-amniotic 
infection/inflammation; and 7) administration of antibiotics (regimen consisted of 
ceftriaxone, clarithromycin, and metronidazole).
Intra-amniotic infection was defined as a positive amniotic fluid culture or positive 
polymerase chain reaction (PCR) assay for Ureaplasma spp., while intra-amniotic 
inflammation was defined as an elevated amniotic fluid IL-6 concentration (≥2.6 ng/mL), as 
previously reported.72,92,109–119 Cervical dilatation was determined by visual examination at 
the time of sterile speculum examination.23,26 Previous studies have shown a good 
correlation between cervical dilatation observed visually and through digital examination.120 
Every effort was made to avoid digital examination to decrease the risk of ascending intra-
amniotic infection.
Amniocentesis was routinely offered to all patients admitted with the diagnosis of cervical 
insufficiency to assess the microbiologic status of the amniotic cavity and the presence of 
intra-amniotic inflammation. This is based on previous studies that report a 52% frequency 
of intra-amniotic infection in patients with cervical insufficiency21 and, in 81% of these 
cases, intra-amniotic inflammation is also present;23 the prognosis under these 
circumstances is poor.21–23,25,26
All patients provided written informed consent. The Institutional Review Board of the Seoul 
National University Hospital approved the collection and use of these samples and clinical 
information for research purposes. The Seoul National University has a Federal Wide 
Assurance with the Office for Human Research Protections (OHRP) of the Department of 
Health and Human Services (DHHS) of the United States.
Amniotic fluid analysis
Amniotic fluid was cultured for aerobic and anaerobic bacteria as well as genital 
mycoplasmas (Ureaplasma spp. and Mycoplasma hominis). Samples were also assayed for 
Ureaplasma spp. using PCR with specific primers, and performed in our clinical 
microbiology laboratory using methods previously described26 at the discretion of the 
attending physician. This test has been available in the clinical microbiology laboratory of 
the Hospital since 2007. A PCR assay for Ureaplasma spp. was performed using stored 
amniotic fluid which was obtained before 2007. An aliquot of amniotic fluid was examined 
in a hemocytometer chamber to determine the white blood cell (WBC) count.57 Between 
March 2005 and December 2010, a rapid MMP-8 bed-side test (MMP-8 PTD Check test, 
SK Pharma Co, Ltd, Kyunggi-do, Korea), was performed and used in patient management. 
Details of the MMP-8 rapid test have been previously described.109,121–123 In a subset of 
patients, MMP-8 concentration in amniotic fluid was measured in our laboratory using a 
commercially available enzyme-linked immunosorbent assay (ELISA) (Amersham Pharmcia 
Biotech, Inc., Bucks, UK) and the results were available to clinicians. Intra-amniotic 
inflammation was suspected when there was an elevated amniotic fluid white blood cell 
count (≥19 cells/mm3),67,121 a positive rapid test for MMP-8,108,123–125 or an MMP-8 
concentration >23 ng/mL).23,81,124,125
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Amniotic fluid not used for clinical diagnostic tests was centrifuged and stored in 
polypropylene tubes at −70°C. The stored amniotic fluid was analyzed for IL-6, which was 
measured using a commercially available enzyme-linked immunoassay (R&D Systems, 
Minneapolis, Minn) in 2017 and 2018. The amniotic fluid IL-6 concentrations were 
measured for research purposes, and the results were not used in clinical decision 
management. The sensitivity of the assay was 0.7 pg/mL. The intra-and inter-assay 
coefficients of variation were <10%. For the purpose of this study, the final diagnosis of 
intra-amniotic inflammation was made when IL-6 concentration was ≥2.6 ng/mL.
Clinical management
Intra-amniotic inflammation, isolation of microorganisms by amniotic fluid culture, or the 
detection of Ureaplasma nucleic acids was an indication for antibiotic administration. We 
used a combination of anti-microbial agents previously described by our group in the 
management of patients with preterm premature rupture of membranes (PROM),123,126 
including ceftriaxone 1g (intravenous) every 24 hours, clarithromycin 500mg (oral) every 12 
hours, and metronidazole (intravenous) 500mg every 8 hours. Metronidazole was 
administered for a maximum of 4 weeks. A follow-up amniocentesis was offered to monitor 
the microbiologic and inflammatory status of amniotic cavity and fetal lung maturity. The 
use and discontinuation of antibiotics, tocolytics and progesterone, interval of follow-up 
amniocentesis, or the placement of a cervical cerclage were left to the discretion of treating 
clinicians because of lack of uniformity among attending physicians. Tocolytics used were 
ritodrine, magnesium sulphate, or atosiban. Non-steroidal anti-inflammatory agents were not 
used as tocolytic agents in this study.
Treatment success
Treatment success was defined as the resolution of intra-amniotic infection/inflammation 
(defined as an IL-6 ≤2.6 ng/ml) or delivery at or after 34 weeks of gestation.
Diagnosis of chorioamnionitis and neonatal morbidity
Acute histologic chorioamnionitis was defined as the presence of acute inflammatory 
changes in the choriodecidua and amnion, respectively; acute funisitis was diagnosed by the 
presence of neutrophil infiltration into the umbilical vessel walls or Wharton’s jelly, using 
previously published criteria.127–131 Clinical chorioamnionitis was diagnosed in the 
presence of a maternal temperature of ≥37.8°C and ≥2 of the following criteria: (1) uterine 
tenderness; (2) malodorous vaginal discharge; (3) maternal leukocytosis (WBC count of 
>15,000 cells/mm3); (4) maternal tachycardia (>100 beats/min); and (5) fetal tachycardia 
(>160 beats/min).132,133
Significant neonatal morbidity was defined as the presence of any of the following 
conditions: respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular 
hemorrhage (grade ≥ II), proven congenital neonatal sepsis, and necrotizing enterocolitis. 
These conditions were diagnosed according to definitions previously described in detail.
127,134
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Continuous variables were compared between two groups using the Mann-Whitney U test. 
Proportions were compared with the Fisher’s exact test. A p-value <0.05 was considered 
statistically significant. Analysis was performed by SPSS, version 22 (SPSS Inc., Chicago, 
IL, USA).
Results
Characteristics of study population
During the study period, 44 patients with cervical insufficiency had one or more 
amniocenteses. Among these patients, stored amniotic fluid was available for IL-6 
determination in 41 patients. Intra-amniotic infection/inflammation was identified in 68% 
(28/41). Among the 28 patients with intra-amniotic infection/inflammation, the antibiotic 
regimen (clarithromycin, ceftriaxone, and metronidazole) was administered in 22 cases. The 
reasons for not using this antibiotic regimen in the other 6 patients included: 1) intra-
amniotic infection/inflammation was not suspected because the patients had a low amniotic 
fluid WBC count when the MMP-8 rapid test was not available (before March 2005 and 
after January 2011) (n=5); however, intra-amniotic inflammation was diagnosed by an 
elevated interleukin-6 concentration measured afterwards; 2) in one patient who had a fever, 
the managing clinician preferred to use another antibiotic regimen.
Twenty-two patients with cervical insufficiency had intra-amniotic infection and/or 
inflammation, and were treated with an anti-microbial agent combination, including 
ceftriaxone, clarithromycin, and metronidazole. Amniotic fluid culture was positive in 2 
patients. Microorganisms identified by culture included Candida albicans (n=1) and 
Streptococcus anginosus (n=1). Intra-amniotic inflammation was identified in 20 patients 
with a negative amniotic fluid culture for microorganisms. In one instance, nucleic acids for 
Ureaplasma spp. were detected using a specific PCR assay.
Figure 1 shows the distribution of patients. Among the 22 patients, six (27%) delivered 
within one week after amniocentesis, and 16 (73%) remained undelivered for at least one 
week after the amniocentesis. A repeat amniocentesis to evaluate the therapeutic response to 
anti-microbial agents was offered to patients and performed in 75% (12/16) of cases. In 75% 
(9/12), there was objective evidence of resolution of intra-amniotic infection or 
inflammation (defined as a negative culture, negative PCR, and amniotic fluid IL-6 <2.6 ng/
mL). Of the four patients who did not have a follow-up amniocentesis, all delivered ≥34 
weeks, two of whom delivered at term (≥37 weeks). Thus, treatment success occurred in 
59% (13/22) of patients with cervical insufficiency and intra-amniotic infection/
inflammation who received the antibiotic regimen (Figure 1).
Table 1 compares the clinical characteristics and outcomes of the patients who delivered 
within one week of amniocentesis and those who remained undelivered for at least one week 
after administration of the antibiotic regimen. Patients who delivered within one week of 
amniocentesis had a significantly higher median amniotic fluid IL-6 concentration and a 
higher rate of history of preterm delivery than those who remained undelivered for at least 
one week after amniocentesis (P=0.005 and P=0.025, respectively). The median amniotic 
Joon et al. Page 6













fluid WBC count and the rate of clinical chorioamnionitis were higher in patients who 
delivered within seven days of amniocentesis than in those who were undelivered for at least 
one week after amniocentesis, however, the differences did not reach statistical significance 
(p>0.05 for each, table 1). Thus, patients with cervical insufficiency who delivered within 
one week of amniocentesis had a more intense intra-amniotic inflammatory response, as 
determined by the concentrations of a soluble component of the inflammatory response (i.e. 
IL-6). Vaginal progesterone was administered to two patients who remained undelivered for 
at least one week.
Among the 16 patients who remained undelivered for one week after amniocentesis, 12 had 
follow-up amniocentesis. The median interval between amniocenteses was 8 days (IQR, 7–
14 days). There were no significant differences in baseline characteristics, results of 
amniotic fluid analysis at the time of the initial amniocentesis, and median gestational age at 
delivery between patients who were undelivered for at least one week and had follow-up 
amniocentesis, and those who had not.
Table 2 displays the clinical characteristics according to the results of amniotic fluid analysis 
obtained at the time of repeat amniocentesis. Resolution of intra-amniotic infection/
inflammation was observed in 75% (9/12) of patients. None of the neonates born to the nine 
mothers with resolution of the intra-amniotic inflammatory response had significant 
complications. The median interval between initial amniocentesis and the follow-up 
amniocentesis that confirmed resolution of intra-amniotic infection/inflammation was 24 
days (interquartile range, 14–30). Among the nine patients, eight delivered at or beyond 34 
weeks of gestation, and six delivered at term. The median gestational age at amniocentesis 
and delivery of patients who delivered at or beyond 34 weeks was 23.4 weeks and 37.8 
weeks, respectively. There were no significant differences in the median amniotic fluid 
WBC count and IL-6 concentration among the three groups of patients (p>0.1).
Changes in amniotic fluid culture, intra-amniotic inflammatory markers, pregnancy and 
neonatal outcomes in patients with follow-up amniocenteses
Table 3 shows the characteristics and outcomes of 12 patients who received antibiotics and 
underwent follow-up amniocentesis. Nine patients (cases 1–9) had biochemical evidence of 
successful treatment of intra-amniotic inflammation. Bulging membranes (defined as the 
prolapse of membranes beyond the external os) were present in 10 of 12 patients (except 
cases 3 and 6). Three of four patients (cases 1, 2, and 4) who did not have cerclage 
placement had spontaneous reduction of membranes back into the uterine cavity while 
receiving antibiotic treatment. This was an unexpected observation made during the course 
of the study.
Of 9 patients in whom the resolution of intra-amniotic inflammation was confirmed by IL-6 
determinations retrospectively, 7 underwent additional amniocentesis after resolution. The 
number of amniocenteses after resolution was 1 for 6 patients and 2 for 1 patient. The 
procedures were performed due to the occurrence of labor or rupture of membranes (n=3), a 
positive result of rapid MMP-8 test at the last amniocentesis (n=1), acute elevation of 
maternal serum C-reactive protein and mild fever (n=1), or re-evaluation of intra-amniotic 
infection/inflammation at the discretion of the clinician caring for the patient (n=2).
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Intra-amniotic infection was eradicated in case 1: Ureaplasma spp. had been detected by 
PCR. This patient had an amniotic fluid IL-6 concentration of 4.8 ng/mL, a WBC count of 
35 cells/mm3, and a positive rapid test for MMP-8 at initial amniocentesis (24.6 weeks). The 
antibiotics were administered after the first amniocentesis. One week later (25.6 weeks), 
membrane rupture occurred but follow-up amniocentesis revealed improvement of 
inflammatory markers (IL-6 concentration of 0.19 ng/mL, WBC count of 6 cells/mm3 and a 
weakly positive MMP-8 rapid kit test). The PCR test for Ureaplasma spp. was still positive. 
The fourth amniocentesis at 27.6 weeks showed no evidence of Ureaplasma spp. by 
cultivation or specific PCR assay, and all parameters of intra-amniotic inflammation 
improved (i.e. IL-6 concentration of 0.17 ng/mL, WBC count of 6 cells/mm3and a negative 
MMP-8 rapid kit test). At 34 weeks of gestation, the patient underwent labor induction 
secondary to preterm PROM. A neonate weighing 2000 grams was delivered and did not 
develop any complications. There was no evidence of acute histologic chorioamnionitis or 
funisitis in placental pathologic examination.
Intra-amniotic infection with Candida albicans was identified in one patient (case #12). 
There was evidence of an intense amniotic fluid inflammatory response (i.e. IL-6 
concentration of 35.4 ng/mL and WBC count of 2556 cells/mm3), and the amniotic fluid 
culture was eventually positive for Candida albicans. A repeat amniocentesis showed a very 
high WBC count (1305 cells/mm3) and the managing physician and patient elected to 
proceed with labor induction because of the concern of congenital candidiasis. The repeat 
amniotic fluid culture showed that Candida albicans was still present. After completion of 
corticosteroid administration for fetal lung maturation, the patient delivered at 28.7 weeks of 
gestation (10 days from initial amniocentesis) after the administration of oxytocin. The 
birthweight was 1100 grams, and Apgar scores at 1 and 5 minutes were 7 and 8, 
respectively. The neonate survived without any significant morbidity and placental 
examination showed acute histologic chorioamnionitis, and funisitis.
Resolution of intra-amniotic inflammation was noted in eight patients with a negative 
amniotic fluid culture and PCR (cases 2–9). Among these, seven delivered at term (cases 3–
8) or near term (case 2, delivered at 36.9 weeks by elective cesarean delivery). One patient 
(case 9) delivered at 29.9 weeks despite the resolution of intra-amniotic inflammation. The 
initial amniotic fluid inflammatory markers were as follows: IL-6 concentration, 3.8 ng/mL 
and WBC count, 4 cells/mm3. After 4 weeks of treatment with the antibiotic regimen, the 
amniotic fluid IL-6 concentration decreased to 1.0 ng/mL and the amniotic fluid WBC count 
was 2 cells/mm3. Antibiotics were discontinued, and the patient was discharged from the 
hospital. Ten days later, the patient was readmitted with spontaneous preterm labor, and the 
amniotic fluid IL-6 concentration had increased to 2.4 ng/mL. The patient progressed to 
spontaneous delivery at 29.9 weeks. The neonate weighed 1610 grams and survived without 
any significant morbidity. Acute histologic chorioamnionitis and funisitis were diagnosed 
upon placental examination.
Antibiotic treatment was not successful in two patients with intra-amniotic inflammation but 
without intra-amniotic infection (cases 10 and 11). Of these two, microbial invasion of 
amniotic cavity (by Candida tropicalis after six weeks of initial amniocentesis in case 10, 
and by Enterococcus faecalis after eight days of initial amniocentesis in case 11) was 
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identified in the follow-up amniocentesis. These two patients delivered at 27.4 weeks (1,220 
gm) and 27 weeks (1,220gm), respectively, because of spontaneous labor. The neonates 
survived but had respiratory distress syndrome (case #10), bronchopulmonary dysplasia 
(cases 10 and 11), and intraventricular hemorrhage (case #10).
Pregnancy and neonatal outcomes in patients who did not have follow-up amniocenteses
Table 4 shows the clinical characteristics and outcomes of four patients who received 
antibiotics and remained undelivered for at least one week after amniocentesis, but did not 
have a follow-up amniocentesis. All four patients underwent an emergency cervical 
cerclage, and antibiotics were postoperatively administered for 4–5 days. Follow-up 
amniocentesis was not performed because there was no evidence of intra-amniotic infection/
inflammation at initial amniocentesis (low amniotic fluid WBC count and negative culture, 
rapid MMP-8 test was not available at this time) in cases 14 and 16, or because of the 
decision made by the attending physician (cases 13 and 15). All patients in this group 
delivered after 34 weeks of gestation.
Table 5 summarizes the characteristics and outcomes of the six patients who delivered 
within one week of amniocentesis and received antibiotics. These patients had a significantly 
higher amniotic fluid IL-6 concentration than those who remained undelivered for at least 
one week after amniocentesis (P=0.005, table 1). The indication of delivery was clinical 
chorioamnionitis (cases 21 and 22), progression of spontaneous labor after PROM (case 19) 
or with intact membranes (case 20), abruptio placentae (case 17), or the patient’s refusal to 
maintain pregnancy (case 18). Only one neonate survived with bronchopulmonary dysplasia 
(case 17) and the other five neonates died shortly after birth.
Comment
Principal findings of the study: 1) Eradication of intra-amniotic inflammation/infection 
was achieved in 75% (9/12) of patients with cervical insufficiency who were treated with 
antimicrobial agents; 2) the overall treatment success (defined as resolution of intra-amniotic 
infection/inflammation or delivery ≥34 weeks) was 59% (13/22). These observations 
provide strong evidence that antibiotic administration can be effective in treating intra-
amniotic inflammation/infection in patients with cervical insufficiency.
The recognition of cervical insufficiency as a clinical entity: The initial 
recognition of cervical insufficiency is attributed to Cole, Culpepper, and Rowland in their 
1658 publication “Practice of Physick”,135 and the term “cervical incompetence” was first 
mentioned in 1865 by Gream.136 In 1950, Lash and Lash described a condition called 
“incompetent internal os of the cervix” as a cause of habitual abortion.137 Currently, the 
term “cervical insufficiency” has replaced “cervical incompetence” to avoid the negative 
connotation of “incompetence”.138 The standard treatment for this treatment, cervical 
cerclage, was introduced in 1955 by Shirodkar139 and in 1957 by McDonald.140 The role of 
cerclage in obstetrics has remained controversial for more than 60 years.15,141–155
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Intra-amniotic infection in cervical insufficiency
Goodlin proposed a role for intra-amniotic infection, and amniocentesis to study the 
microbial status of the amniotic cavity and decompression of the uterus by removing 
amniotic fluid prior to placement of a cerclage.20 Goodlin reported that 22.2% (2/9) of 
patients with cervical insufficiency had microorganisms in the amniotic cavity (one had 
Escherichia coli and the other had Group β streptococcus).20 He proposed treatment of intra-
amniotic infection with the administration of ampicillin into the amniotic cavity at the time 
of amniocentesis. The patient with Group β streptococcus carried the pregnancy to term, 
suggesting a therapeutic value for antibiotic administration.20
Subsequent studies have shown that microorganisms are present in the amniotic cavity in 8–
52% of patients with cervical insufficiency.20–27 For example, in one study including 33 
patients with cervical insufficiency, 51.5% (17/33) had a positive amniotic fluid culture for 
microorganisms.21 Four of these patients had a cervical cerclage because the amniotic fluid 
Gram stain results were negative. All had complications, which consisted of rupture of 
membranes, clinical chorioamnionitis, or bleeding. When a cervical cerclage was not placed 
in patients with intra-amniotic infection, all (13/13) had a preterm delivery. On the other 
hand, patients without intra-amniotic infection had a favorable outcome, suggesting that the 
microbial status of the amniotic cavity is a major determinant of pregnancy outcome in 
patients with cervical insufficiency.
Intra-amniotic inflammation in cervical insufficiency
Microbial products (endotoxin or lipopolysaccharide, peptidoglycans, and glucans) and 
microorganisms can elicit an inflammatory response.31–45 In practice, it is easier and faster 
to diagnose intra-amniotic inflammation than intra-amniotic infection, because an elevated 
amniotic fluid WBC count or inflammatory molecules (such as IL-6 or MMP-8) can be 
rapidly detected in clinical practice, while the results of amniotic fluid culture or molecular 
microbiologic techniques will take longer than a bedside test.109,117–119,121–123,156,157 It is 
now recognized that some cases of intra-amniotic inflammation occur in the absence of 
demonstrable microorganisms detected with cultivation or molecular methods (“sterile intra-
amniotic inflammation”)72,98–100,113,115,125 and this condition is more common than intra-
amniotic infection in patients with a sonographic short cervix.78,113 The same has been 
reported in patients with cervical insufficiency with the use of cultivation techniques.23
Specifically, Lee et al.23 reported that 81% (42/52) of patients with cervical insufficiency 
had evidence of intra-amniotic inflammation, defined as an amniotic fluid concentration of 
MMP-8 >23 ng/mL. Only four patients in that study had evidence of intra-amniotic infection 
using cultivation methods. Therefore, most cases of intra-amniotic inflammation were not 
attributed to bacteria. The prevalence of intra-amniotic inflammation in other studies has 
ranged from 22.2% (16/72) to 64.5% (20/31) using different cutoffs of IL-6 concentrations 
for the definition of intra-amniotic inflammation.94,95
The prognosis of patients with cervical insufficiency and intra-amniotic inflammation is 
poor, with 50% delivering within seven days, and, in 84% of cases, patients have a preterm 
delivery at <34 weeks.23 Importantly, Lee et al. reported that there were no differences in the 
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amniocentesis-to-delivery interval or the rate of adverse pregnancy outcome between 
patients with intra-amniotic inflammation and a negative amniotic fluid culture and patients 
with proven intra-amniotic infection.23 Collectively, these data suggest that intra-amniotic 
inflammation is a poor prognostic factor in cervical insufficiency.
Antimicrobial agents to treat cervical insufficiency
In this study, clinicians elected to use a combination of ceftriaxone, clarithromycin, and 
metronidazole based on previous studies of the pharmacokinetics of antibiotics during 
pregnancy.158,159 The rationale has been described in previous reports.123,126 In brief, 
erythromycin or azithromycin were frequently inadequate in eradicating intra-amniotic 
infection with Ureaplasma species, the most common microorganism identified in the 
amniotic fluid of patients at risk for preterm delivery, perhaps due to limited trans-placental 
passage, which results in inadequate antimicrobial activity in amniotic fluid (only 3% of 
erythromycin and 2.6% of azithromycin cross the placenta).158 Clarithromycin, on the other 
hand, has a much higher rate of transplacental passage, and is effective for the treatment of 
intra-amniotic infection with Ureaplasma species.158 Metronidazole was used because of its 
powerful effect against anaerobic bacteria which are frequently implicated in intra-amniotic 
infection.160–163 These organisms are difficult to identify using cultivation techniques.164 
Ceftriaxone was included because of its enhanced coverage of aerobic bacteria and high rate 
of transplacental passage.159,165 In a previous study, we demonstrated successful eradication 
of intra-amniotic infection and/or inflammation in at least 33% of patients with preterm 
PROM after the administration of this antibiotic regimen.123
Can intra-amniotic infection be treated in patients with cervical insufficiency?
Goodlin20 reported the successful treatment of intra-amniotic infection in one case after the 
administration of a single dose of 1 gram of ampicillin into the amniotic cavity. However, 
since that report in 1979, there is a paucity of investigation about the treatment of intra-
amniotic infection and inflammation. Antibiotics have been successful in eradicating 
amniotic fluid infection in animal models.166,167 Fidel et al.166 reported that antibiotic 
administration within 12 h of transcervical inoculations of E.coli, but not after 18 h, 
increased the duration of pregnancy (by reducing the rate of preterm delivery) and neonatal 
survival in rabbits. More recently, Grigsby et al.167 showed that maternal azithromycin can 
eradicate Ureaplasma spp. from the amniotic fluid and key fetal organs in a non-human 
primate model. Gravett et al.168 reported that the combination of immunomodulators 
(dexamethasone and indomethacin) and antibiotics was able to eradicate intra-amniotic 
infection, suppress intraamniotic and placental inflammation, and prolong gestation in a 
non-human primate model.
The results reported herein show that antibiotic administration can eradicate intra-amniotic 
infection, as demonstrated by repeat amniotic fluid analyses of one patient who had 
Ureaplasma spp. detected by PCR at 24.6 weeks of gestation. This patient delivered at 34 
weeks and the neonate had no significant morbidity. In contrast, one patient was admitted at 
27.4 weeks, received antibiotics, and the amniotic fluid culture eventually became positive 
for Candida albicans. A repeat amniocentesis showed a very high WBC count (1305 
cells/mm3) and the managing physician and patient elected to proceed with labor induction 
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because of the concern of congenital candidiasis. The repeat amniotic fluid culture showed 
that Candida albicans was still present. Such observation underscores the importance of 
knowing the specific microorganism involved and selecting antibiotics which are effective 
against the pathogen. Previous reports have shown that fluconazole may be effective in cases 
of intra-amniotic infection with Candida albicans.169
Antibiotics can eradicate intra-amniotic inflammation in cervical insufficiency
An observation made during the course of this case series is that antibiotic administration in 
patients with intra-amniotic inflammation was effective in treating intra-amniotic 
inflammation, even when microorganisms were not detectable. We have reported similar 
results in patients with preterm PROM.123,126
The mechanisms whereby antibiotics can treat intra-amniotic inflammation are not clear. 
One possibility is that these agents are effective against microorganisms that were not 
detected using cultivation techniques,99,113,114,164,170–177 or PCR-specific assays for 
Ureaplasma spp. Future studies using broad-range PCR assays or cell-free microbial 
DNA178–181 could help answer this important question.
It is also possible that macrolides (i.e. clarithromycin) suppress intra-amniotic inflammation 
caused by danger signals by downregulating the expression of pro-inflammatory 
transcription factors, such as nuclear factor κ-B (NFκ-B) and activator protein-1 (AP-1), 
which can induce the production of pro-inflammatory cytokines. Such observations have 
been made in other organ systems.182–184 It is unlikely that antibiotics were effective in 
reducing decidual infection because careful studies to locate microorganisms in the 
chorioamniotic membranes and decidua have shown that organisms first invade the amniotic 
cavity, and only are secondarily present in the decidua. Thus, the initial view that organisms 
would be present in the decidua, and from there invade the amniotic cavity, is contradicted 
by empirical evidence using morphologic and molecular microbiologic techniques.185
A relevant question is the relative contribution of antibiotics and cervical cerclage to the 
outcomes in this study. There are no data to support that cervical cerclage alone can 
eradicate intra-amniotic inflammation. A cervical cerclage was placed in 64% of patients, 
and may have had a beneficial effect in improving pregnancy outcome. However, it can be 
postulated that some patients with intra-amniotic infection/inflammation benefitted from the 
administration of the combination of antimicrobial agents, which eradicated bacteria from 
the amniotic cavity or downregulated the inflammatory response.
In patients in whom infection or inflammation was successfully treated, a cervical cerclage 
may have contributed to the prevention of preterm labor or pregnancy loss by closing the 
cervix and preventing further exposure of the chorioamniotic membranes to microorganisms 
present in the vagina. Therefore, the improved clinical outcomes observed in this study may 
have been due to the combination of antibiotic administration, with a direct effect on 
microbial invasion of the amniotic cavity and intra-amniotic inflammation, and cerclage, 
which prevented re-infection or recurrence of the inflammatory process. A cerclage may also 
have had a protective role by supporting the cervix, as cervical disorders may be a cause of 
preterm labor and midtrimester pregnancy loss.
Joon et al. Page 12














This is an observational study in which women with intra-amniotic infection/inflammation 
were treated with antibiotics and monitored with follow-up amniocenteses. It represents an 
objective demonstration that a case of intra-amniotic infection was successfully treated, and 
that intra-amniotic inflammation could also be down-regulated and followed by a favorable 
pregnancy outcome.
Although Goodlin20 reported the first case of eradication of intra-amniotic infection in 
cervical insufficiency, the current study reports the successful treatment of intra-amniotic 
inflammation in the absence of detectable microorganisms. This was possible because of the 
availability of rapid tests for detection of intra-amniotic inflammation, such as amniotic fluid 
WBC count and a rapid amniotic fluid test for MMP-8. It is unlikely that the eradication of 
intra-amniotic inflammation can be attributed to the administration of corticosteroids, 
because these agents were not administered in 69.2% (9/13) of patients in whom treatment 
was successful.
A limitation of this study is that it is not a randomized clinical trial, but rather a case series, 
and therefore, further studies to confirm these observations are desirable. Another limitation 
is that we combined patients with intra-amniotic infection and those with intraamniotic 
inflammation but without proven intra-amniotic infection. Lee et al. previously demonstrated 
that these two conditions have similar pregnancy outcomes.23 Additional research is 
required to examine whether there is a differential effect of antibiotics in patients with intra-
amniotic infection vs those with “sterile” intra-amniotic inflammation. The main claim of 
this paper is that antimicrobial agents can be useful in eradicating intra-amniotic 
inflammation and, in some cases, intra-amniotic infection. While our data suggest that the 
frequency of complications in the neonatal period is lower, other studies will need to 
examine long-term follow-up.
This study included patients with cervical insufficiency diagnosed by physical examination, 
and therefore, does not address the entity of an asymptomatic short cervix diagnosed by 
ultrasound. We previously demonstrated that microbial invasion of the amniotic cavity in 
asymptomatic patients with a short cervix can be treated with antibiotics, as demonstrated by 
repeat amniocentesis in which amniotic fluid cultures became negative, and patients 
delivered close to term.186
The choice of antimicrobial agents used in this study, route of administration, and duration 
of treatment represent the choice of clinicians practicing in a University hospital that has 
studied intra-amniotic infection/inflammation, the microbiology of infection, and the short-
and long-term consequences of these conditions. It is possible that similar success could be 
achieved with other antibiotic regimens which provide adequate coverage for the most 
frequent microorganisms found in the amniotic cavity (genital mycoplasmas) and 
administered in a different manner.
Medicine is evolving towards the individualized treatment of patients, and we believe that, 
with the application of modern molecular microbiologic techniques, it may be possible to 
tailor treatment for a specific patient based on the results of amniotic fluid analysis.
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Antibiotic administration to women with cervical insufficiency and intra-amniotic infection/
inflammation can eradicate these pathologic processes in a subset of patients.
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AJOG at a Glance:
A. What is the research question?
Can intra-amniotic infection/inflammation in patients with cervical 
insufficiency be treated with antibiotics?
B. What are the key findings?
75% of patients with intra-amniotic infection/inflammation had objective 
evidence of resolution of the intra-amniotic inflammatory process after 
treatment with antibiotics.
C. What does this add to what is known?
The conventional view is that cervical insufficiency complicated by intra-
amniotic infection/inflammation leads to inevitable delivery. Herein we 
present the first objective evidence that intra-amniotic infection/inflammation 
can be eradicated with antibiotic treatment, as proven by serial amniotic fluid 
analysis before and after treatment. This has implications for optimizing 
patient care.
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Flow diagram of the study population
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Table 1.
Clinical characteristics and outcomes of patients with cervical insufficiency who received antimicrobial 
agents. Patients are classified into those who delivered within 1 week of amniocentesis and those who 
remained undelivered for at least 1 week
Delivery before 1 week (n=6) Delivery after 1 week (n=16) p-value
Maternal age (years) 35 (28–38) 32 (24–39) 0.97
Nulliparity 16.7% (1/6) 43.8% (7/16) 0.35
History of preterm delivery 66.7% (4/6) 12.5% (2/16) 0.025
GA at amniocentesis (weeks) 22.2 (19.7–25.0) 23.2 (21.3–27.4) 0.29
Positive amniotic fluid culture 16.7% (1/6) 6.3% (1/16) 0.48
Positive amniotic fluid polymerase chain reaction for Ureaplasma 
spp.
0% (0/4) 7.1% (1/14) 1.00
Amniotic fluid white blood cell count (cells/mm3) 143 (0–430) 7 (0–2556) 0.070
Amniotic fluid white blood cell count ≥ 19 cells/mm3 83.3% (5/6) 31.3% (5/16) 0.056
Amniotic fluid interleukin-6 (ng/mL) 47.7 (5.7–49.3) 9.4 (2.8–35.4) 0.005
Amniotic fluid interleukin-6 ≥ 2.6 ng/mL 100% (6/6) 100% (16/16) 1.00
Cervical dilatation > 3cm 83.3% (5/6) 68.8% (11/16) 0.63
Cervical cerclage for cervical insufficiency 33.3% (2/6) 75.0 % (12/16) 0.14
Use of tocolytics 66.7% (4/6) 37.5% (6/16) 0.34
Use of natural vaginal progesterone 0% (0/6) 12.5% (2/16) 1.00
Use of 17α-hydroxyprogesterone caproate 0% (0/6) 0% (0/16) 1.00
Antenatal corticosteroids administration 33.3% (2/6) 43.8% (7/16) 1.00
Gestational age at delivery (weeks) 23.0 (20.0–25.7) 37.0 (27.0–41.3) <0.001
Preterm labor
a 33.3% (2/6) 18.8% (3/16) 0.59
Preterm premature rupture of membranes
a 33.3% (2/6) 6.3% (1/16) 0.17
Clinical chorioamnionitis 33.3% (2/6) 0% (0/16) 0.065
Acute histologic chorioamnionitis 75% (3/4) 57.1% (4/7) 1.00
Funisitis 25% (1/4) 42.9% (3/7) 1.00
Data are median (range) or % (n/N).
a
Cases in which preterm delivery before 37 weeks occurred were included.
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Table 2.
Antenatal and postnatal characteristics of patients who were treated with antimicrobial agents and underwent 
follow-up amniocentesis after 1 week from initial amniocentesis
Resolution of intra-amniotic inflammation
Confirmed (n=9) Not confirmed (n=3)
Delivery ≥ 34 weeks (n=8) Delivery < 34 weeks 
(n=1)
Delivery < 34 weeks (n=3)
Nulliparity 50% (4/8) 100% (1/1) 33.3% (1/3)
History of preterm delivery 12.5% (1/8) 0% (0/1) 0% (0/3)
Initial amniocentesis
  Gestational age at amniocentesis 23.4 (21.0–26.7) 23.7 21.4 (21.3–27.4)
  Positive amniotic fluid culture 0% (0/8) 0% (0/1) 33.3% (1/3)
    Positive amniotic fluid polymerase chain reaction 
for Ureaplasma spp.
14.3% (1/7) 0% (0/1) 0% (0/3)
  Amniotic fluid white blood cell count (cells/mm3) 16 (0–282) 4 24 (1–2556)
  Amniotic fluid interleukin-6 (ng/mL) 8.9 (2.8–26.2) 3.8 24.8 (10.6–35.4)
Days from initial amniocentesis to resolution
a 23 (6–30) 30 -
Number of amniocenteses 3.5 (3–7) 3 4 (3–5)
Duration of new antibiotic regimen use (days) 27 (7–66) 31 39 (9–43)
Cervical dilatation > 3cm (%) 75% (6/8) 100% (1/1) 100% (3/3)
Cervical cerclage for cervical insufficiency 50% (4/8) 100% (1/1) 100% (3/3)










Clinical chorioamnionitis 0% (0/8) 0% (0/1) 0% (0/3)
Acute histologic chorioamnionitis 0% (0/3) 100% (1/1) 100% (3/3)
Funisitis 0% (0/3) 100% (1/1) 66.7% (2/3)
Neonatal mortality 0% (0/8) 0% (0/1)- 0% (0/3)
Significant neonatal morbidity 0% (0/8) 0% (0/1)- 66.7% (2/3)
Data are median (range) or % (n/N).
a
The first amniocentesis without evidence of intra-amniotic infection/inflammation
b
P-value < 0.05
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